Dbv Technologies SA Form 4 insider transactions

Pharis Mohideen, Chief Medical Officer of DBV Technologies S.A., sold 464 shares of common stock on July 29, 2026 for $2.70 per share.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 534 ordinary shares for $4.86 each to cover tax obligations related to restricted stock unit vesting.

Baker Bros. Advisors LP and its affiliated funds exercised significant warrants in DBV Technologies S.A. following the successful VITESSE Phase 3 study.

The Bpifrance group, a 10% owner of DBV Technologies S.A., reported the sale of over 3.3 million ordinary shares across multiple transactions in mid-December 2025.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, reported sales of ordinary shares to cover tax obligations and received new restricted stock units and employee stock options.

DBV Technologies S.A.'s Chief Financial Officer, Virginie Boucinha, was granted 32,000 restricted stock units and 192,000 employee stock options.

DBV Technologies' Chief Commercial Officer, Kevin Michael Trapp, acquired 55,000 restricted stock units and 316,250 employee stock options.

DBV Technologies S.A. CEO Daniel Tasse was granted 964,000 employee stock options with an exercise price of $2.9, vesting over four years.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 464 ordinary shares to cover tax obligations related to restricted stock unit vesting.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 397 ordinary shares to cover tax obligations related to restricted stock unit vesting.

Baker Bros. Advisors and related entities acquired pre-funded warrants in DBV Technologies through a private placement expected to close around April 7, 2025.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 600 ordinary shares at $0.85 per share to cover withholding tax obligations related to vesting restricted stock units.

DBV Technologies CEO Daniel Tasse was granted 813,200 stock options on December 4, 2024, which will vest in four equal annual installments starting December 4, 2025.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold a total of 907 ordinary shares to cover tax obligations related to vesting restricted stock units.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, acquired shares through a restricted stock unit grant and sold shares to cover tax obligations, while also receiving a new stock option grant.

DBV Technologies' Chief Financial Officer, Virginie Boucinha, acquired 19,000 ordinary shares and 113,000 stock options on November 21, 2024.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 1,785 ordinary shares to cover withholding tax obligations, retaining a beneficial ownership of 79,367 shares.

Pharis Mohideen, Chief Medical Officer of DBV Technologies S.A., sold a total of 1,042 ordinary shares in two transactions on May 22 and May 24, 2024.

CEO Daniel Tasse reports acquiring and disposing of DBV Technologies S.A. ordinary shares on March 8, 2024.